<DOC>
	<DOCNO>NCT01131104</DOCNO>
	<brief_summary>Study H6D-MC-LVHQ observational , non-interventional , multi-center , prospective , case-crossover study evaluate possible association use phosphodiesterase type 5 ( PDE5 ) inhibitor risk acute nonarteritic anterior ischemic optic neuropathy ( NAION ) male . Subjects newly diagnose NAION ask via structured questionnaire use PDE5 inhibitor risk factor prior onset vision loss .</brief_summary>
	<brief_title>A Study Determine There Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy ( NAION ) Phosphodiesterase Type 5 ( PDE5 ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Adult male subject , least 18 year age , willing participate study Patients experience abrupt visual loss one eye ( define typically less 1day period visual loss note upon awaken ) present initial visit within 45 day onset NAION symptom ophthalmologist resulted diagnosis Suspected NAION investigator Previous history NAION Previous history arteritis ( anywhere body ) clinical diagnostic test evidence temporal arteritis History glaucoma either one eye History multiple sclerosis diagnostic test evidence optic neuritis Have dementia reason memory impairment opinion investigator Have participate nonobservational study within 3 month NAION onset</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NAION</keyword>
</DOC>